Early Phase 1 N=12 Ivermectin and Human Immunity
Ivermectin
Primary: The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded. — 0; 0; 0; 0 Cytokines changed from t=0
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=167 Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
Severe Acute Respiratory Syndrome · Ventilation Pneumonitis
Primary: Patients Who Improved Their Condition or Did Not Worsen it — 135; 12; 19 Participants
Phase 2 N=399 A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
COVID-19
Primary: COVID-19 Prophylaxis — 30; 105 Participants
Phase 3 N=340 Prophylactic Ivermectin in COVID-19 Contacts
COVID
Primary: Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath) — 15; 59 Participants
Phase 3 N=66 Ivermectin for Severe COVID-19 Management
COVID-19
Primary: Gender Distribution of the Patients — 19; 21; 11; 9 Participants
Phase 3 N=630 Clinical Endpoint Study of Ivermectin 1% Cream
Moderate to Severe Papulopustular Rosacea
Primary: Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea. — -64.87; -64.87; -55.04 percentage of change from baseline…
Phase 1 N=16 Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
COVID 19
Primary: Number of Cured Patients — 16 Participants
Phase 3 N=1,459 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)
Covid19
Primary: Time to Sustained Recovery in Days — 11; 12 days
Phase 3 N=2,712 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Malaria · Lymphatic Filariasis
Primary: Incidence of Clinical Malaria Episodes — 2.49; 2.00 episodes
Phase 2 N=11 Development of Ivermectin for Alcohol Use Disorders
Alcohol Use Disorder
Primary: Heart Rate — 64.57; 68.36; 66.82; 62.82 BPM — p=0.0563
Phase 3 N=1,800 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)
Covid19
Primary: Time to Sustained Recovery in Days — 12; 13 days
Phase 2 N=66 Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
COVID-19
Primary: Participants With a Disease Control Status Defined as no Disease Progression to Severe. — 30; 26 Participants
Phase 3 N=911 Clinical Endpoint Study of Ivermectin 0.5% Lotion
Head Lice
Primary: Percentage of Index Participants Who Were Considered a Treatment Success: PP Population — 90.9; 89.0 percentage of participants
Phase 3 N=371 A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
Head Lice
Primary: Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 71…
Phase 3 N=164 Moxidectin for LF, Cote d'Ivoire (DOLF)
Lymphatic Filariasis
Primary: Clearance of Microfilaremia (IA vs. MoxA) — 8; 18; 24; 27 Participants
Phase 2 N=24 Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial
Covid-19 · Coronavirus Infection · SARS-CoV-2 Infection
Primary: Proportion of Patients With a Positive SARS-CoV-2 PCR — 12; 12; 11; 12 Participants
Phase 3 N=410 A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation
Head Lice
Primary: Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 76…
Phase 3 N=400 Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
Covid19
Primary: Number of Patients With Early Clinical Improvement — 111; 80 Participants — p=<0.03
Phase 2 N=260 Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 17.5; 50.0; 83.3; 84.6 percentage of participants cured (%)
Phase 2 N=30 Rosacea and Ivermectin
Rosacea
Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants
Phase 2 N=247 Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
Head Lice
Primary: Percentage of Participants With Treatment Success Following Treatment With Either Ivermectin or Placebo (Vehicle Control) — 95; 53; 83; 49 Percent of Participants
Phase 3 N=4,124 Repeat Ivermectin Mass Drug Administrations for MALaria Control II
Malaria
Primary: Malaria Incidence — 0.0176; 0.0183 Malaria cases per person-week
Phase 4 N=190 MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
Rosacea
Primary: Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA): — 53; 35…
Phase 2 N=25 Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
Rosacea
Primary: Relative Trypsin-like Enzyme Activity — 1.10 percentage of baseline
Phase 3 N=1,800 ACTIV-6: COVID-19 Study of Repurposed Medications
Covid19
Primary: Total Number of Participants Randomized Within Each Appendix — 1800; 1331; 1407; 1459 Participants
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
Phase 3 N=332 Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Cure Rate Against Strongyloides Stercoralis — 94.8; 99.4 percentage of participants
Phase 3 N=962 CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Papulopustular Rosacea
Primary: Percent Change in Inflammatory Lesions From Baseline to Week 16 — -83; -73.7 percentage of change
Phase 2 N=22 Dose-finding Study of Moxidectin for Treatment of Scabies
Scabies
Primary: Mortality Rate for Adult Scabies Mites — 2; 6; 8; 14 Adult mites
Phase 2 N=78 Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation
Pediculus Humanus Capitis (Head Lice)
Primary: Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 56; 50…